HIV treatment

Topics in this section

HIV treatment: latest news

HIV treatment resources

HIV treatment features

HIV treatment in your own words

HIV treatment news from aidsmap

More news

HIV treatment news selected from other sources

  • AIDS treatment Visconti’s coup

    If the common factor between so-called post-treatment controllers can be identified, it will allow doctors to offer treatment withdrawal to those likely to benefit from it. It will also show researchers a chink in AIDS’s armour. If they can find something which they can insert into that chink to clear the disease in other people, too, the Visconti trial may come to be seen as a turning point in the war on AIDS.

    15 March 2013 | The Economist

  • Texas: Food availability linked with poor outcomes for HIV-positive children

    An HIV-positive child whose family does not have enough good food available is more likely to have a poor clinical outcome, researchers reported. They found that children who did not always have enough to eat had lower CD4 counts as well as higher chances of incomplete viral suppression.

    12 February 2013 | Baylor College of Medicine press release

  • EMA: Viracept: Non-renewal of the marketing authorisation in the European Union

    Before the expiry of the last 5-year period of validity the Marketing Authorisation Holder did not apply to renew the marketing authorisation. Consequently, the marketing authorisation for Viracept expired on 23 January 2013.

    07 February 2013 | European Medicines Agency

  • Suboptimal Suppression with Maraviroc plus a Boosted Protease Inhibitor?

    Until larger studies are done, such regimens are probably best avoided.

    05 February 2013 | Journal Watch

  • Uganda: Health Ministry Sets New Treatment Guidelines

    The health ministry has released new national clinical guidelines for the management of common conditions. It also released new essential medicines and health supplies list for HIV/AIDS, malaria, TB, pneumonia and diarrhoea in children.

    01 February 2013 | AllAfrica

  • Médecins Sans Frontières addresses study by Massachusetts General Hospital on implications of switching from branded to generic antiretrovirals for HIV

    The just-released study stating that switching patients from the branded combination antiretroviral ‘Atripla’ to generics could be therapeutically ‘less effective’ is misleading and misses a big part of the picture. The harmful role played by patents in blocking the use of quality-assured generic combination drugs is overlooked. The article further conflates evidence that single-pill "fixed-dose combination" HIV drugs lead to better treatment outcomes with the false notion that generic medicines themselves may lead to worse outcomes.

    17 January 2013 | MSF / EATG

  • Phone texts fail to boost adherence to HIV therapy

    Mobile phone text messaging does not considerably enhance HIV/AIDS patients' adherence to treatment, a study conducted in Cameroon reveals.

    10 January 2013 | SciDev NET

  • Top 12 HIV and Hepatitis Stories of 2012

    HIVandHepatitis.com reviews some the year's major HIV and viral hepatitis news highlights. On the HIV front, U.S. treatment guidelines recommended antiretroviral therapy (ART) for all HIV positive people, Truvada was approved for pre-exposure prophylaxis (PrEP), and HIV criminalization and cure research were highlighted at the International AIDS Conference in July. Promising findings were reported for several interferon-free oral regimens for hepatitis C, experimental tuberculosis (TB) drugs showed good results, and the Affordable Care Act remained on track.

    03 January 2013 | HIVandHepatitis.com

  • HIV patients in care lose more years of life to smoking than to HIV infection

    Among HIV patients receiving well-organized care with free access to antiretroviral therapy, those who smoke lose more years of life to smoking than to HIV, according to a Danish study published in Clinical Infectious Diseases and available online.

    21 December 2012 | EurekAlert

  • ViiV Healthcare announces regulatory submissions for dolutegravir in the EU, US and Canada

    ViiV Healthcare today announced the submission of regulatory applications in the European Union (EU), United States (US) and Canada for the investigational integrase inhibitor dolutegravir (S/GSK1349572) for the treatment of HIV infection in adults and adolescents.

    18 December 2012 | ViiV press release
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.

See also